<DOC>
	<DOCNO>NCT00983398</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose melphalan give together carboplatin , mannitol , sodium thiosulfate , see well work treat patient recurrent progressive central nervous system ( CNS ) embryonal germ cell tumor . Drugs use chemotherapy , melphalan carboplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Osmotic blood-brain barrier disruption ( BBBD ) use mannitol open blood vessel around brain allow cancer-killing substance carry directly brain . Sodium thiosulfate may help lessen prevent hearing loss toxicity patient undergo chemotherapy carboplatin BBBD . Giving melphalan together carboplatin , mannitol , sodium thiosulfate may effective treatment recurrent progressive CNS embryonal germ cell tumor .</brief_summary>
	<brief_title>Melphalan , Carboplatin , Mannitol , Sodium Thiosulfate Treating Patients With Recurrent Progressive CNS Embryonal Germ Cell Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) intra-arterial ( IA ) melphalan give IA carboplatin , osmotic BBBD delay intravenous ( IV ) sodium thiosulfate ( STS ) subject recurrent progressive embryonal germ cell tumor CNS . ( Phase I ) II . To estimate response rate subject recurrent progressive CNS embryonal germ cell tumor treat IA carboplatin , IA melphalan , osmotic BBBD delay IV STS . ( Phase II ) SECONDARY OBJECTIVES : I . To describe 2-year progression-free survival ( PFS ) overall survival ( OS ) rate subject recurrent progressive CNS embryonal germ cell tumor treat IA carboplatin , IA melphalan , osmotic BBBD delay IV STS . ( Phase II ) II . To describe neuropsychological audiology outcome subject recurrent progressive CNS embryonal germ cell tumor treat IA carboplatin , IA melphalan , osmotic BBBD delay IV STS . ( Phase II ) III . To describe overall toxicity IA carboplatin IA melphalan conjunction osmotic BBBD delay STS chemoprotection subject recurrent progressive CNS embryonal germ cell tumor . ( Phase II ) OUTLINE : This phase I , dose-escalation study melphalan follow phase II study . Patients receive mannitol IA 30 second , melphalan IA 10 minute , carboplatin IA 10 minute . Patients receive sodium thiosulfate IV 15 minute 4 8 hour carboplatin . Treatment repeat every 4-6 week 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 6 month 1 year , annually 3 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>Subjects histologically confirm CNS embryonal tumor ( primitive neuroectodermal tumor [ PNET ] , medulloblastoma , atypical teratoid rhabdoid tumor [ ATRT ] , medulloepithelioma , pineoblastoma ependymoblastoma ) , germ cell tumor , eligible ; tumor must relapse refractory firstline therapy ; diagnosis make basis compute tomography ( CT ) assist stereotactic biopsy , open biopsy , surgical resection , cerebrospinal fluid ( CSF ) cytology , elevate tumor marker Subjects must prior therapy accord best available therapy determine primary brain tumor specialist ( include oncology , neurosurgery and/or radiation oncology ) include systemic and/or cranial spinal radiation chemotherapy ; least 14 day must elapse since completion cranial radiotherapy 28 day since completion chemotherapy ; least 28 day must elapse since completion total spine radiotherapy Subjects previous radiotherapy treatment must consultation radiation oncologist provider must discussion context NeuroOncology Tumor Board within 60 day prior start IA/BBBD chemotherapy determine need radiotherapy prior IA/BBBD For phase II portion study , subject must disease evaluable response ; subject radiation site disease eligible unless image evidence active tumor , ie : increase blood volume Glomerular filtration rate ( GFR ) creatinine clearance ( CrCl ) ( 24 hour urine ) great 30 ml/min correct body surface area Absolute granulocyte count &gt; = 1.0 x 10^3/mm^3 Platelets &gt; = 100 x 10^3/mm^3 Creatinine &lt; 1.5 Total bilirubin &lt; 2.0 mg/dl Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 2.5 x upper limit normal Subject 's Karnofsky performance status ( KPS ) must &gt; = 50 % ( Eastern Cooperative Oncology Group [ ECOG ] performance score &lt; 3 ) ; Lansky scale use subject less 16 year age must &gt; = 50 % Subjects legal guardian must sign write informed consent accordance institutional guideline Sexually active woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study treatment duration study treatment ; female become pregnant suspect pregnant participating study , inform treat physician immediately Subjects radiographic sign excessive intracranial mass effect associate rapid neurologic deterioration and/or spinal cord block Subjects significant risk general anesthesia Subjects uncontrolled ( last 30 day ) clinically significant confound medical condition Subject pregnant lactating Subjects contraindication carboplatin , melphalan , STS</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>